Breaking News
Start for Free 0
🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% each
Unlock Stocks
Close

UCB SA (UCB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
183.55 0.00    0.00%
12/11 - Real-time Data. Currency in EUR
Type:  Equity
Market:  Austria
ISIN:  BE0003739530 
  • Volume: 0
  • Bid/Ask: 181.05 / 182.25
  • Day's Range: 180.15 - 183.55
UCB 183.55 0.00 0.00%

UCB Company Profile

 
Explore the UCB company profile for core details about UCB, assess UCB company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryPharmaceuticals
SectorHealthcare
Employees

8767

Equity Type

DRC

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Contact Information

Address Allée de la Recherche, 60
Brussels, 1070
Belgium
Phone 32 2 559 99 99
Fax 32 2 559 99 00

Top Executives

Name Age Since Title
Jonathan M. Peacock 65 2021 Independent Chair of the Board
Jan Berger 67 2019 Independent Director
Jean-Christophe Tellier 65 2014 CEO & Executive Director
Susan Gasser 69 2021 Independent Director
Cyril Janssen 53 2015 Director
Charles-Antoine Emmanuel T. Janssen 53 2012 Director
Ulf Arne Wiinberg 66 2016 Independent Director
Pierre L. Gurdjian 63 2016 Independent Director
Jonkheer Cédric van Rijckevorsel 54 2014 Director
Gerhard N. Mayr 78 2005 Honorary Chairman
Georges Jacobs de Hagen 84 2005 Honorary Chairman
Diégo du Monceau de Bergendal 74 1984 Honorary Chairman
Mark Eyskens - 2005 Honorary Chairman
Dame Kay Davies 73 2014 Independent Director
Maelys Castella 58 2023 Independent Director
Guy Keutgen - 1990 Honorary Director
Jean-Louis Vanherweghem - - Honorary Director
Gaëtan van de Werve - 2006 Honorary Director
Jean-Pierre Kinet 71 2008 Honorary Director
Alice Dautry 74 2015 Honorary Director
Prince Lorenz - 2001 Honorary Director
Peter J. Fellner 81 2005 Honorary Director
Alan John Blinken - - Honorary Director
Frederic Roch Doliveux 68 2005 Honorary Director
Arnoud de Pret Roose de Calesberg 80 2005 Honorary Director
Norman J. Ornstein 76 2008 Honorary Director
Thomas Fulton Wilson McKillop 81 2009 Honorary Director
Jean van Rijckevorsel - 1992 Honorary Director
Rodolfo J. Savitzky 62 2024 Independent Director
Dolca Thomas 54 2024 Independent Director
Nefertiti Greene 53 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

UCB Comments

Write your thoughts about Ucb SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email